News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivir AB (MVIRb.F) Release: Positive Results From a Phase Ia Study With MIV-711 for the Treatment of Skeletal Disorders



5/21/2013 9:29:19 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Stockholm, Sweden – Medivir AB (OMX:MVIR) announced that data from a first in man study on the investigational cathepsin K inhibitor MIV-711 for the treatment of osteoarthritis and osteoporosis was presented today at the European Calcified Tissue Society (ECTS) Annual Meeting in Lisbon, Portugal.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES